Science Explorer Back to mapMap
Discussion
Institution · German Center for Lung Research

Most cited papers from German Center for Lung Research

German Center for Lung Research

What are the most cited papers from German Center for Lung Research?

The most cited paper from German Center for Lung Research is "Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer" (Leena Gandhi et al., 2018), with 6,764 citations. Next come "2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension" (3,956) and "Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary" (3,296).

Showing 50 of 57 papers. Every paper with more than 780 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer Leena Gandhi et al. · New England Journal of Medicine Open access 16 Apr 2018 6,764
2 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension Marc Humbert et al. · European Heart Journal Open access 26 Aug 2022 3,956
3 Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary Claus Franz Vogelmeier et al. · American Journal of Respiratory and Critical Care Medicine Open access Mar 2017 3,296
4 Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden Matthew David Hellmann et al. · New England Journal of Medicine Open access 16 Apr 2018 3,185
5 Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition) 1 Daniel J. Klionsky et al. · Autophagy Open access2,930 authors 2 Jan 2021 2,743
6 First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer David Paul Carbone et al. · New England Journal of Medicine Open access 21 Jun 2017 2,602
7 SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues Carly G.K. Ziegler et al. · Cell Open access121 authors 27 Apr 2020 2,500
8 Comprehensive genomic profiles of small cell lung cancer Julie George et al. · Nature Open access 10 Jul 2015 2,448
9 Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up David Planchard, Sanjay Popat, Keith M. Kerr et al. · Annals of Oncology Open access 26 Jul 2018 2,331
10 Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele Peter Gordon Middleton et al. · New England Journal of Medicine Open access 31 Oct 2019 2,211
11 Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019 Dave Singh et al. · European Respiratory Journal Open access 7 Mar 2019 1,992
12 Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment Jonas Schulte-Schrepping et al. · Cell Open access140 authors 5 Aug 2020 1,642
13 68 Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer Clemens Kratochwil, Paul Flechsig, Thomas Lindner et al. · Journal of Nuclear Medicine Open access 6 Apr 2019 1,506
14 Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report Harold R. Collard et al. · American Journal of Respiratory and Critical Care Medicine 14 Jun 2016 1,486
15 Ceritinib in ALK -Rearranged Non–Small-Cell Lung Cancer Alice Tsang Shaw et al. · New England Journal of Medicine Open access 26 Mar 2014 1,479
16 Diagnostic criteria for Menière's disease Jose Antonio Lopez-Escamez, John P. Carey, Won-Ho Chung et al. · Journal of Vestibular Research Open access Mar 2015 1,473
17 Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension Tomás Pulido, Igor Adzerikho, Richard N. Channick et al. · New England Journal of Medicine Open access 28 Aug 2013 1,457
18 Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial Naiyer A. Rizvi et al. · The Lancet Oncology Open access 19 Feb 2015 1,436
19 Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial Harry G.M. Heijerman et al. · The Lancet Open access Nov 2019 1,420
20 Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension Hossein-Ardeschir Ghofrani, Andrea Maria D’Armini, Friedrich Grimminger et al. · New England Journal of Medicine Open access 24 Jul 2013 1,408
21 Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer David R. Spigel et al. · Journal of Clinical Oncology Open access 2 Feb 2022 1,400
22 First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial Luis G Paz-Ares et al. · The Lancet Oncology 18 Jan 2021 1,396
23 Riociguat for the Treatment of Pulmonary Arterial Hypertension Hossein-Ardeschir Ghofrani, Nazzareno Galiè, Friedrich Grimminger et al. · New England Journal of Medicine Open access 24 Jul 2013 1,361
24 Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial Edward B. Garon et al. · The Lancet Open access 2 Jun 2014 1,321
25 Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary Alvar G.N. Agustí et al. · European Respiratory Journal Open access Mar 2023 1,320
26 Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives Marc Humbert, Christophe Guignabert, Sébastien Bonnet et al. · European Respiratory Journal Open access 13 Dec 2018 1,295
27 The Human Phenotype Ontology in 2021 Sebastian Köhler et al. · Nucleic Acids Research Open access 16 Nov 2020 1,280
28 Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50% Martin Reck, Delvys Rodríguez‐Abreu, Andrew George Robinson et al. · Journal of Clinical Oncology Open access 19 Apr 2021 1,182
29 Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer Shirish M. Gadgeel et al. · Journal of Clinical Oncology Open access 9 Mar 2020 1,181
30 Best practices for single-cell analysis across modalities Lukas Heumos et al. · Nature Reviews Genetics ReviewOpen access 31 Mar 2023 1,135
31 COVID-19 severity correlates with airway epithelium–immune cell interactions identified by single-cell analysis Robert Lorenz Chua et al. · Nature Biotechnology Open access 26 Jun 2020 1,131
32 Mapping the human genetic architecture of COVID-19 COVID-19 Host Genetics Initiative et al. · Nature Open access3,896 authors 8 Jul 2021 1,130
33 Treatable traits: toward precision medicine of chronic airway diseases Alvar G.N. Agustí, Elisabeth H. Bel, Mike D. Thomas et al. · European Respiratory Journal Open access 31 Jan 2016 1,088
34 A global view of pulmonary hypertension Marius M. Hoeper, Marc Humbert, Rogério Souza et al. · The Lancet Respiratory Medicine 11 Mar 2016 1,074
35 Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma Parameswaran K. Nair, Sally E. Wenzel, Klaus Friedrich Rabe et al. · New England Journal of Medicine Open access 22 May 2017 1,056
36 Iron deficiency Sant‐Rayn Pasricha, Jason A. Tye–Din, Martina Ulrike Muckenthaler et al. · The Lancet 4 Dec 2020 1,053
37 SARS‐CoV‐2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells Soeren Lukassen, Robert Lorenz Chua, Timo B. Trefzer et al. · The EMBO Journal Open access 14 Apr 2020 1,027
38 Chronic thromboembolic pulmonary hypertension Nick H. Kim, Marion Delcroix, Xavier Jaïs et al. · European Respiratory Journal Open access 13 Dec 2018 1,016
39 Chronic obstructive pulmonary disease Klaus Friedrich Rabe, Henrik Watz · The Lancet May 2017 997
40 A cellular census of human lungs identifies novel cell states in health and in asthma Felipe A. Vieira Braga et al. · Nature Medicine Open access 17 Jun 2019 991
41 Physical Activity Is the Strongest Predictor of All-Cause Mortality in Patients With COPD Benjamin Waschki, Anne Marie Kirsten, Olaf Holz et al. · CHEST Journal 27 Jan 2011 970
42 Inflammation following acute myocardial infarction: Multiple players, dynamic roles, and novel therapeutic opportunities Sang‐Bing Ong, Sauri Hernández‐Reséndiz, Gustavo E Crespo-Avilan et al. · Pharmacology & Therapeutics Open access 9 Jan 2018 965
43 Chronic lung allograft dysfunction: Definition, diagnostic criteria, and approaches to treatment―A consensus report from the Pulmonary Council of the ISHLT Geert M. Verleden, Allan R. Glanville, Erika D. Lease et al. · The Journal of Heart and Lung Transplantation Open access 3 Apr 2019 959
44 Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial Martin Reck et al. · The Lancet Respiratory Medicine 26 Mar 2019 954
45 Estimated Global Proportions of Individuals With Persistent Fatigue, Cognitive, and Respiratory Symptom Clusters Following Symptomatic COVID-19 in 2020 and 2021 Global Burden of Disease Long COVID Collaborators et al. · JAMA Open access128 authors 10 Oct 2022 939
46 EAACI Molecular Allergology User's Guide Paolo Maria Matricardi et al. · Pediatric Allergy and Immunology Open access May 2016 926
47 Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up Lizza E.L. Hendriks, Keith M. Kerr, Jessica Menis et al. · Annals of Oncology Open access 23 Jan 2023 856
48 An integrated cell atlas of the lung in health and disease Lisa Sikkema et al. · Nature Medicine Open access Jun 2023 834
49 Diagnostic criteria for persistent postural-perceptual dizziness (PPPD): Consensus document of the committee for the Classification of Vestibular Disorders of the Bárány Society Jeffrey P. Staab, Annegret Eckhardt‐Henn, Arata Horii et al. · Journal of Vestibular Research Open access 10 Oct 2017 833
50 CellRank for directed single-cell fate mapping Marius Lange, Volker Bergen, Michal Klein et al. · Nature Methods Open access 13 Jan 2022 825

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.